Composition for suppressing increase in blood PCSK9 concentration

D-psicose ingestion addresses the limitations of existing PCSK9-targeting drugs by safely and affordably suppressing PCSK9 levels, thereby reducing LDL cholesterol and associated health risks.

JP7595271B2Active Publication Date: 2024-12-06MATSUTANI CHEM IND CO LTD +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2019029686
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2019-02-21
Publication Date
2024-12-06
Estimated Expiration
2039-02-21

AI Technical Summary

Technical Problem

Current drugs targeting PCSK9 for lowering LDL cholesterol are expensive, have low productivity, and pose side effects, necessitating a more affordable and safer alternative.

Method used

A composition containing D-psicose as an active ingredient, ingested daily at 0.1 to 0.5 g/kg body weight for at least 28 days, effectively suppresses PCSK9 concentration in the blood.

Benefits of technology

D-psicose ingestion significantly reduces PCSK9 concentration, potentially lowering LDL cholesterol and reducing the risk of arteriosclerotic diseases with minimal side effects and cost.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595271000004
    Figure 0007595271000004
  • Figure 0007595271000005
    Figure 0007595271000005
  • Figure 0007595271000001
    Figure 0007595271000001
Patent Text Reader

Abstract

To provide compositions and the like that suppresses an increase in PCSK9 concentration in blood, which is one of the causes of dyslipidemia.SOLUTION: The above subject can be solved by using D-psicose as an active ingredient, since D-psicose suppresses an increase in PCSK9 concentration in blood.SELECTED DRAWING: Figure 2
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a composition for suppressing an increase in blood PCSK9 concentration, etc. [Background technology]

[0002] In recent years, the number of patients developing dyslipidemia (hypercholesterolemia, hyperlipidemia) and resulting arteriosclerosis due to obesity caused by a shift to a high-calorie, high-cholesterol diet and poor lifestyle habits has been rapidly increasing, making it urgent to take measures.

[0003] Currently, HMG-CoA reductase inhibitors (statins) are approved as one of the treatments for hypercholesterolemia. However, although statins strongly lower LDL (low-density lipoprotein) cholesterol, they have the problem that they cannot be administered in high doses because of the increased risk of rhabdomyolysis as a side effect. Therefore, there has been a demand for the development of a drug that has a different mechanism of action from statins and has the effect of lowering LDL cholesterol.

[0004] Meanwhile, PCSK9 (Proprotein Convertase Subtilisin / Kexin type 9), which regulates the metabolism of LDL receptors by binding to them and breaking them down, has recently been attracting attention. Although the role of PCSK9 in the body is still unclear, it has been shown that suppressing the expression of PCSK9 reduces blood LDL cholesterol. Blood LDL cholesterol is taken up into cells by the LDL receptors present on the cell surface, but when PCSK9 is overexpressed, the LDL receptors are broken down and the receptors become insufficient. This leads to insufficient uptake of blood LDL cholesterol into cells, which results in an increase in blood LDL cholesterol, and an increased risk of arteriosclerosis and other diseases.

[0005] Therefore, currently, development of pharmaceuticals and the like that inhibit the activity of PCSK9 in the blood or suppress the expression of PCSK9 is underway. For example, Patent Document 1 discloses fully human monoclonal antibodies (mAbs) that specifically bind to human PCSK9 (hPCSK9) and antigen-binding fragments thereof, and Patent Document 2 discloses antisense nucleotides that target PCSK9 mRNA and conjugates thereof.

[0006] However, although these antibody and nucleic acid drugs are highly specific and effective, they currently have low productivity and are expensive, which places a large economic burden on patients who require long-term treatment, and some patients may experience side effects. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] Special Publication No. 2012-511913 [Patent Document 2] Special Publication No. 2016-523094 Summary of the Invention [Problem to be solved by the invention]

[0008] Therefore, an object of the present invention is to provide a composition or agent for suppressing an increase in blood PCSK9 concentration that is inexpensive and has few side effects. [Means for solving the problem]

[0009] The present inventors conducted various studies on PCSK9 and unexpectedly discovered that continuous intake of D-psicose can suppress an increase in blood PCSK9 concentration.

[0010] That is, the present invention has been completed based on the above findings, and comprises the following [1] to [7]. [1] A composition for suppressing an increase in blood PCSK9 concentration, comprising D-psicose as an active ingredient. [2] The composition according to the above [1], for allowing the ingestion of 0.1 g to 0.5 g of D-psicose per kg of body weight per day. [3] The composition according to the above [1], for continuously ingesting 0.1 g to 0.5 g of D-psicose per kg of body weight per day for at least 28 days. [4] An agent that suppresses elevated blood PCSK9 concentrations, containing D-psicose as its active ingredient. [5] The agent according to the above [4] for allowing a subject to take in 0.1 g to 0.5 g of D-psicose per kg of body weight per day. [6] The agent according to the above [4], for allowing a subject to continuously ingest 0.1 g to 0.5 g of D-psicose per kg of body weight per day for at least 28 days. [7] A method of suppressing the increase in blood levels of PCSK9 by having patients take 0.1 to 0.5 g of D-psicose per kg of body weight per day for at least 28 consecutive days. Effect of the Invention

[0011] By ingesting the composition for suppressing an increase in blood PCSK9 concentration, which contains D-psicose as an active ingredient, of the present invention, an increase in blood PCSK9 concentration can be suppressed. [Brief description of the drawings]

[0012] [Figure 1] FIG. 1 is a diagram showing the procedure of a test (Example 3) on the first and last days of continuous ingestion of a sample (15 g of D-psicose). [Diagram 2] FIG. 1 shows the average blood PCSK9 concentrations of all subjects (14 subjects) from whom blood was drawn on the first and last days of continuous sample intake (Example 3). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] In the present invention, the "inhibition of increase" of blood PCSK9 concentration means that the blood PCSK9 concentration does not increase relatively after taking a sample. Specifically, the blood PCSK9 concentration of each subject who takes a sample for a certain period of time and collects blood before and after taking the sample is measured using a commercially available kit (for example, "CircuLex Human PCSK9 ELISA Kit" or "CircuLex Mouse / Rat PCSK9 ELISA Kit" manufactured by CircuLex Corporation), and the like, and the blood PCSK9 concentration after taking the sample does not increase compared to the blood PCSK9 concentration before taking the sample.

[0014] D-psicose in the present invention is most simply produced using an enzyme (epimerase) from D-fructose as a raw material, but is not limited to that produced enzymatically and may also be that produced chemically.

[0015] The daily intake of D-psicose, which is the active ingredient of the present invention, is required to be at least 0.05 g / kg body weight, preferably 0.1 g to 0.5 g / kg body weight, more preferably 0.2 to 0.5 g / kg body weight, and even more preferably 0.2 to 0.4 g / kg body weight. The composition or agent of the present invention is preferably designed so that such a dose can be ingested.

[0016] The intake period of the composition for suppressing an increase in blood PCSK9 concentration in the present invention is at least 14 days, preferably 28 days, and more preferably 56 days.

[0017] The method of ingestion of the composition or agent for suppressing an increase in blood PCSK9 concentration in the present invention is not particularly limited, but for example, it can be orally ingested in the form of an aqueous solution, tablet, granule, etc., and if it is an aqueous solution, it can also be administered by subcutaneous injection. The timing of ingestion may be before, during, or after a meal, but is preferably before or during a meal, and more preferably before a meal.

[0018] The composition or agent for suppressing an increase in blood PCSK9 concentration in the present invention can also be incorporated into food and drink. For example, it can be incorporated into bakery foods, noodles, snack foods such as okonomiyaki, takoyaki, and pancakes, Japanese sweets, fish pastes, fried batter, fritters, yogurt, puddings, jellies, dressings including mayonnaise and sauces, thickened sauces, frozen desserts such as ice cream, meat products, cooked rice, powdered drinks, soft drinks, carbonated drinks, and various drinks such as jellies, but is not particularly limited thereto.

[0019] The present invention will be specifically described below with reference to examples, but the present invention is not limited to these examples. EXAMPLES

[0020] <Continuous D-psicose intake test in hamsters> The effect of D-psicose intake on the PCSK9 concentration in the blood of hamsters was confirmed. The experimental animals were 16 male Golden Syrian hamsters (hereinafter referred to as hamsters) aged 5 weeks and 16 male hamsters aged 4 weeks. First, the 16 hamsters aged 5 weeks were pre-bred for 1 week, and then divided into two groups, a control intake group and a 3% D-psicose intake group (8 animals per group), and were bred for 8 weeks with free access to normal experimental feed (hereinafter referred to as normal feed) according to the composition in Table 1 and water. Thereafter, blood was collected from each hamster. Next, the 16 hamsters aged 4 weeks were pre-bred for 1 week, and then free access to high-fat experimental feed (hereinafter referred to as high-fat feed) according to the composition in Table 1 and water for 4 weeks to induce obesity.

[0021] After the induction of obesity, the hamsters were divided into two groups (8 animals per group), a control group and a 3% D-psicose group, and were kept with free access to high-fat diet and water for 4 weeks. After that, blood was collected from each hamster.

[0022] [Table 1]

[0023] <Measurement and Results of Blood PCSK9 Concentration in Hamsters> The blood PCSK9 concentration of the above-mentioned hamsters (32 animals) was measured using a commercially available kit (CircuLex Mouse / Rat PCSK9 ELISA Kit manufactured by Cyclex). Table 2 shows the average value of the blood PCSK9 concentration of each individual grouped together.

[0024]

Table 2

[0025] As a result, in the 3% D-psicose intake group on a normal diet, the blood PCSK9 concentration was significantly decreased compared to the control intake group (Example 1). Also, in the 3% D-psicose intake group on a high-fat diet, the blood PCSK9 concentration was significantly decreased compared to the control intake group (Example 2).

[0026] The hamsters raised were ingesting an average of 205 kcal / kg body weight of food per day, and the daily intake energy was calculated to be approximately 6.1 times that of a human (body weight 60 kg). The hamsters raised were ingesting an average of 1.5 g / kg body weight of D-psicose per day, which is 6 times the intake amount (0.25 g / kg body weight) when a human (body weight 60 kg) ingests 15 g / day of D-psicose. Therefore, the D-psicose intake amount of the hamsters raised is equivalent to the case when a human (body weight 60 kg) ingests 15 g of D-psicose per day.

[0027] <D-psicose Continuous Intake Test in Humans> Next, the effect on the blood PCSK9 concentration in humans by continuous intake of D-psicose was confirmed. The subjects were men aged 20 or older and under 70 years old, untreated patients with hypercholesterolemia (120 mg / dl ≤ fasting LDL-C < 160 mg / dl: 7 subjects) and untreated patients with borderline diabetes with an expected increase in LDL cholesterol value (110 mg / dl ≤ fasting blood glucose value < 126 mg / dl, or 6.2 < HbA1c (NGSP) < 6.5: 7 subjects).

[0028] The total intake period was 56 days, and for the 54 days excluding the first and last days of intake, the intake method was as follows: 15 g of the sample D-psicose was taken with water or the like once a day within 1 hour before any meal.

[0029] The following test was conducted at the test facility for the first and last two days of taking 15g of D-psicose (Figure 1). After the subjects were examined by a doctor at the test facility one hour before the start of the test, they took 15g of D-psicose (the time when the intake started was the start of the test). Blood samples were taken from each subject every two hours from just before the start of the test to 10 hours after. Immediately after taking 15g of D-psicose, the subjects took a designated breakfast with 150ml of water over 15 minutes, and 4 hours after the start of the test, the subjects took a designated lunch and 8 hours after the start of the test, each with 150ml of water over 15 minutes. In addition, 6 hours after the start of the test, 150ml of water was taken. The blood samples taken from each subject were used to measure PCSK9.

[0030] <Measurement and results of PCSK9 concentration in human blood> The blood PCSK9 concentrations of all the subjects (14 people) were measured using a commercially available kit (CircuLex Human PCSK9 ELISA Kit, manufactured by CircuLex). The average and standard deviation of the blood PCSK9 concentrations of each individual for all subjects are shown in Table 3 and Figure 2.

[0031] [Table 3]

[0032] As a result, the PCSK9 concentration in blood drawn just before the start of the test on the final day was lower than that at the same time on the first day (Figure 2: 0 hr). In addition, the PCSK9 concentration in blood 2 and 4 hours after the start of the test on the final day was significantly lower than that at the same time on the first day (Figure 2: 2-4 hr). Furthermore, the PCSK9 concentration in blood 6-10 hours after the start of the test on the final day was even more significantly lower than that at the same time on the first day (Figure 2: 6-10 hr).

[0033] As described above, an increase in blood PCSK9 concentration can be suppressed by ingestion of D-psicose, and therefore a composition for suppressing an increase in blood PCSK9 concentration, etc., which contains D-psicose as an active ingredient, can be provided, and ingestion of such a composition, etc. is expected to reduce LDL cholesterol in the blood.

Claims

1. A composition for suppressing an increase in blood PCSK9 concentration, comprising D-psicose as an active ingredient.

2. The composition according to claim 1, for allowing a subject to take in 0.1 g to 0.5 g of D-psicose per kg of body weight per day.

3. The composition according to claim 1, for continuously ingesting 0.1 g to 0.5 g of D-psicose per kg of body weight per day for at least 28 days.

4. An agent for suppressing an increase in blood PCSK9 concentration, the active ingredient of which is D-psicose.

5. The agent according to claim 4, for allowing a subject to take in 0.1 g to 0.5 g of D-psicose per kg of body weight per day.

6. The agent according to claim 4, for allowing a subject to continuously ingest 0.1 g to 0.5 g of D-psicose per kg of body weight per day for at least 28 days.

Citation Information

Patent Citations

  • High affinity human antibody for PCSK9

    JP2012511913A

  • Antisense oligomers and conjugates targeting PCSK9

    JP2016523094A

  • Method for inhibiting lipid absorption and / or promoting lipid excretion using D-psicose

    JP2018530600A